Latest Posts
About This Stock
More About This Stock
Read
ImmunoCellular Receives SPA From FDA For Phase 3 Trial In Glioblastoma
Article By:
Terry Chrisomalis
Thursday, August 13, 2015 11:02 AM EDT
Shares of ImmunoCellular are up 24% after the company received an SPA from the FDA for a phase 3 trial in Glioblastoma.
In this article: IMUC